HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen

Scott A. Wu; Dan Tong Jia; Margaret Schwartz; Mary Mulcahy; Kuanghua Guo; Matthew C. Tate; Sean Sachdev; Nicolas Kostelecky; David J. Escobar; Daniel J. Brat; Amy B. Heimberger; Rimas V. Lukas

doi:10.2217/cns-2022-0018

HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen

Scott A. Wu, Dan Tong Jia, Margaret Schwartz, Mary Mulcahy, Kuanghua Guo, Matthew C. Tate, Sean Sachdev, Nicolas Kostelecky, David J. Escobar, Daniel J. Brat, Amy B. Heimberger, Rimas V. Lukas^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Materials & methods: We recently reported the largest trial of breast cancer patients with HER2 positive leptomeningeal metastases (LM) treated with trastuzumab. An additional treatment indication was explored as part of a single institution retrospective case series of HER2 positive esophageal adenocarcinoma LM (n = 2). Results: One patient received intrathecal trastuzumab (80 mg twice weekly) as part of their treatment regimen with durable long-term response and clearance of circulating tumor cells in the cerebral spinal fluid. The other patient demonstrated rapid progression and death as previously described in the literature. Conclusion: Intrathecal trastuzumab is a well-tolerated and reasonable therapeutic option worthy of further exploration for patients with HER2 positive esophageal carcinoma LM. An associative, but not a causal relationship, can be made regarding therapeutic intervention.

Original language	English (US)
Article number	CNS99
Journal	CNS oncology
Volume	12
Issue number	3
DOIs	https://doi.org/10.2217/cns-2022-0018
State	Published - May 23 2023

Funding

Authors SA Wu, DT Jia, M Mulcahy, K Guo, MC Tate, S Sachdev, N Kostelecky, DJ Escobar and DJ Brat declare that they have no financial interests. Author M Schwartz has received compensation for serving as a speaker for Novocure Inc. Author RV Lukas has received compensation for serving as a speaker for Novocure Inc. and Merck and consulting fees from Novocure Inc. and Merck as well as research support (drug only) from BMS. AB Heimberger has received consulting fees from WCG Oncology and Caris Life Science and research support from Alnylam and AbbVie. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Keywords

HER2
circulating tumor cells
esophageal cancer
intrathecal
leptomeningeal metastases
trastuzumab

ASJC Scopus subject areas

Neurology
Clinical Neurology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/cns-2022-0018

Cite this

@article{a3410b95bcb24471918167758126a62a,

title = "HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen",

abstract = "Materials & methods: We recently reported the largest trial of breast cancer patients with HER2 positive leptomeningeal metastases (LM) treated with trastuzumab. An additional treatment indication was explored as part of a single institution retrospective case series of HER2 positive esophageal adenocarcinoma LM (n = 2). Results: One patient received intrathecal trastuzumab (80 mg twice weekly) as part of their treatment regimen with durable long-term response and clearance of circulating tumor cells in the cerebral spinal fluid. The other patient demonstrated rapid progression and death as previously described in the literature. Conclusion: Intrathecal trastuzumab is a well-tolerated and reasonable therapeutic option worthy of further exploration for patients with HER2 positive esophageal carcinoma LM. An associative, but not a causal relationship, can be made regarding therapeutic intervention.",

keywords = "HER2, circulating tumor cells, esophageal cancer, intrathecal, leptomeningeal metastases, trastuzumab",

author = "Wu, {Scott A.} and Jia, {Dan Tong} and Margaret Schwartz and Mary Mulcahy and Kuanghua Guo and Tate, {Matthew C.} and Sean Sachdev and Nicolas Kostelecky and Escobar, {David J.} and Brat, {Daniel J.} and Heimberger, {Amy B.} and Lukas, {Rimas V.}",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors.",

year = "2023",

month = may,

day = "23",

doi = "10.2217/cns-2022-0018",

language = "English (US)",

volume = "12",

journal = "CNS oncology",

issn = "2045-0907",

publisher = "Future Medicine Ltd.",

number = "3",

}

TY - JOUR

T1 - HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen

AU - Wu, Scott A.

AU - Jia, Dan Tong

AU - Schwartz, Margaret

AU - Mulcahy, Mary

AU - Guo, Kuanghua

AU - Tate, Matthew C.

AU - Sachdev, Sean

AU - Kostelecky, Nicolas

AU - Escobar, David J.

AU - Brat, Daniel J.

AU - Heimberger, Amy B.

AU - Lukas, Rimas V.

PY - 2023/5/23

Y1 - 2023/5/23

N2 - Materials & methods: We recently reported the largest trial of breast cancer patients with HER2 positive leptomeningeal metastases (LM) treated with trastuzumab. An additional treatment indication was explored as part of a single institution retrospective case series of HER2 positive esophageal adenocarcinoma LM (n = 2). Results: One patient received intrathecal trastuzumab (80 mg twice weekly) as part of their treatment regimen with durable long-term response and clearance of circulating tumor cells in the cerebral spinal fluid. The other patient demonstrated rapid progression and death as previously described in the literature. Conclusion: Intrathecal trastuzumab is a well-tolerated and reasonable therapeutic option worthy of further exploration for patients with HER2 positive esophageal carcinoma LM. An associative, but not a causal relationship, can be made regarding therapeutic intervention.

AB - Materials & methods: We recently reported the largest trial of breast cancer patients with HER2 positive leptomeningeal metastases (LM) treated with trastuzumab. An additional treatment indication was explored as part of a single institution retrospective case series of HER2 positive esophageal adenocarcinoma LM (n = 2). Results: One patient received intrathecal trastuzumab (80 mg twice weekly) as part of their treatment regimen with durable long-term response and clearance of circulating tumor cells in the cerebral spinal fluid. The other patient demonstrated rapid progression and death as previously described in the literature. Conclusion: Intrathecal trastuzumab is a well-tolerated and reasonable therapeutic option worthy of further exploration for patients with HER2 positive esophageal carcinoma LM. An associative, but not a causal relationship, can be made regarding therapeutic intervention.

KW - HER2

KW - circulating tumor cells

KW - esophageal cancer

KW - intrathecal

KW - leptomeningeal metastases

KW - trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=85169019269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85169019269&partnerID=8YFLogxK

U2 - 10.2217/cns-2022-0018

DO - 10.2217/cns-2022-0018

M3 - Article

C2 - 37219390

AN - SCOPUS:85169019269

SN - 2045-0907

VL - 12

JO - CNS oncology

JF - CNS oncology

IS - 3

M1 - CNS99

ER -

HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this